Slide 1: Q3/9M 2024 Results
Q3/9M 2024 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 12, 2024
Slide 2: Executive summary, Financial overview, Guidance 2024, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2024, growth story “We are creating the leading 4 Appendix European Specialty Pharma platform to treat diseases optimally with individualized medicine.” Matthias Gärtner, CEO Medios AG 2
Slide 3: Highlights Q3 2024
Executive summary Highlights Q3 2024 Significant earnings and margin growth in 9M 24 following record Q3 24 • Q3 24: disproportionate 42.9% EBITDA pre increase; outstanding EBITDA pre margin of 5.0% Financials • PST with strong EBITDA pre growth > 10%, PST and Ceban (International Business, IB) driv
Slide 4: European Compounding Platform
Executive summary European Compounding Platform • Leading position in Specialty Pharma compounding in Europe following acquisition of Ceban • 10 GMP* -(compliant) facilities • 8 GMP labs for individualized preparations in Germany and The Netherlands • 2 API1 repackaging facilities in Antwerp, Belgiu
Slide 5: QoQ – Record revenue and EBITDA pre; outstanding EBITDA pre margin
Financial overview QoQ – Record revenue and EBITDA pre; outstanding EBITDA pre margin Revenue (€m) EBITDA pre¹ €m 24.6 490 493 431 441 456 451 419 422 393 399 399 17.2 16.1 15.3 15.0 15.1 14.1 14.3 14.1 14.3 11.1 5.0% EBITDA 5.0 pre1 3.6 3.6 3.6 3.4 3.5 3.3 3.5 3.2 3.3 3.6 margin Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 6: YoY Q3 2024 – Record Quarter
Financial overview YoY Q3 2024 – Record Quarter Revenue in €m EBITDA pre¹ in €m 0.7% 42.9% 489.9 493.2 17.2 24.6 EBITDA pre 5.0% margin 3.5% Q3 2023 Q3 2024 Q3 2023 Q3 2024 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for
Slide 7: YoY 9M 2024: Disproportionate EBITDA pre growth
Executive summary YoY 9M 2024: Disproportionate EBITDA pre growth Revenue in €m EBITDA pre¹ in €m 4.2% 20.6% 1,343 1,401 46.3 55.8 EBITDA pre 4.0% margin 3.4% 9M 2023 9M 2024 9M 2023 9M 2024 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pr
Slide 8: Executive summary, Financial overview, Guidance 2024, Appendix
1 Executive summary 2 Financial overview 3 Guidance 2024, growth story 4 Appendix 8
Slide 9: 9M 2024 – Good Group financials and strong operating CF
Financial overview 9M 2024 – Good Group financials and strong operating CF In € million 9M 2024 9M 2023 ∆ in % Comments Revenue 1,400.5 1,343.5 4.3% Financials including the strong contribution of Ceban (segment International Business “IB”) for four months Gross profit1 107.3 83.6 28.3% gross margin
Slide 10: 9M 2024 – Revenue growth driven by Ceban and PS contribution
Financial overview 9M 2024 – Revenue growth driven by Ceban and PS contribution YoY revenue in €m 9M 23 Organic Inorganic 9M 24 Comments Pharmaceutical Supply (PS) 1,168.0 23.2 - 1,191.2 • Ceban acquisition led to revenue contribution of €47.3m (4 months) in International Business Patient-Specific T
Slide 11: 9M 2024 – EBITDA pre growth driven by strong four months Ceban contribution
Financial overview 9M 2024 –EBITDA pre growth driven by strong four months Ceban contribution EBITDA pre1 in €m 9M 23 Organic Inorganic 9M 24 Comments Pharmaceutical Supply (PS) 33.7 3.3 - 37.0 • EBITDA pre of PS grew organically (€3.3m) • Decreased EBITDA pre1 of PST is mainly a result of Patient-S
Slide 12: 9M - Strong PS and IB (four months); PST impacted by regulatory effects
Financial overview 9M - Strong PS and IB (four months); PST impacted by regulatory effects Pharmaceutical Patient-specific International Internal IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' Services consolidation YoY in € million 9M 24 9M 23 9M 24 9M 23 9M 24 9M 23 9M 24 9M 23 9M 24 9M 23 9
Slide 13: Status Debt-Financing
Financial overview Status Debt-Financing • Net debt of approx. €166m on 30 September 2024 • Includes fully drawn bridge loan for Ceban acquisition of €200m, syn loan not drawn as of 30 September 2024 • Envisaged new financing structure: €225m, thereof • €125m as term loan, term: 5 yrs, repayment wil
Slide 14: 1 Executive summary 2 Financial overview 3 Guidance 2024, growth story
1 Executive summary 2 Financial overview 3 Guidance 2024, growth story 4 Appendix “Medios delivers the best quality – reliably, competently and fast. These are key criteria for the optimal care of our patients.” 14
Slide 15: New Group: Significant revenue & EBITDA pre increase expected
Guidance 2024 confirmed Guidance 2024 & growth story New Group: Significant revenue & Revenue (€bn) At least 1.9 - 2.1 EBITDA pre increase expected + 5.6% Guidance confirmed: • One month later than planned consolidation of ~1.8 Ceban as of June 1, 2024 (previously as of May 1, 2024 expected); regula
Slide 16: Clear strategy to build the leading European Specialty Pharma Platform
Medios at a Glance Clear strategy to build the leading European Specialty Pharma Platform Strengthening Expansion Diversification the Core Business of Compounding Advanced in Germany in Europe Therapies Continue evolving out Expand compounding Become a trusted partner compounding infrastructure with
Slide 17: 1 Executive summary 2 Financial overview 3 Guidance 2024, growth story
1 Executive summary 2 Financial overview 3 Guidance 2024, growth story 4 Appendix “I work for Medios because I can contribute to patient care that meets the highest quality standards.” 17
Slide 18: Snapshot Ceban Pharmaceuticals
Key Investment Highlights Snapshot Ceban Pharmaceuticals • Leading full-service compounding services platform • Diversified business model covering the full compounding value chain: Founded Headquarters Employees − Compounding Services (non-sterile and sterile) 2004 Breda, Netherlands ~600 − API1 Se
Slide 19: Synergistic positions across the compounding value chain
Appendix Synergistic positions across the compounding value chain Compounding Services API Services Pharmacies • Tailor-made medication • Sourcing, repacking and • 23 owned pharmacies across compounded at GMP-compliant distributing APIs and excipients the Netherlands under the facilities for pharmac
Slide 20: Transformative and value enhancing acquisition
Appendix Transformative and value enhancing acquisition • First step in Medios internationalization Internationalization • Immediate market entry into three European countries: NL, BE, ES • A leading position in compounding in Northwestern Europe • First building block to establish the leading Europ
Slide 21: Q3 – Record quarter: Disproportionate EBITDA pre increase with outstanding margin
Financial overview Q3 – Record quarter: Disproport. EBITDA pre increase with outstanding margin Pharmaceutical Patient-specific International Internal Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' Services IFRS consolidation Group YoY in € million Q3 24 Q3 23 Q3 24 Q3 23 Q3 24 Q3 23 Q3 24 Q3 23 Q3 24 Q3
Slide 22: Q3 2024: Reflects focus on high-margin revenue
Financial overview Q3 2024: Reflects focus on high-margin revenue YoY Revenue in €m Q3 23 Organic Inorganic Q3 24 Comments Pharmaceutical Supply (PS) 433.9 -30.6 - 403.3 • Inorganic growth driven by Ceban acquisition Patient-Specific Therapies (PST) 56.0 -2.0 - 54.1 International Business (IB) 35.7
Slide 23: Q3 2024 – Disproportionate EBITDA pre growth
Financial overview Q3 2024 – Disproportionate EBITDA pre growth YoY EBITDA pre1 in €m Q3 23 Organic Inorganic Q3 24 Comments Pharmaceutical Supply (PS) 13.8 0.4 - 14.2 • Successful integration of Ceban led to EBITDA pre1 contribution of €7.1m Patient-Specific Therapies (PST) 5.3 0.5 - 5.9 • Services
Slide 24: Key figures (1/2)
Appendix Key figures (1/2) in € thousand 9M 2024 9M 2023 ∆ in % Q3 2024 Q3 2023 ∆ in % Revenue 1,400,505 1,343,458 4.2% 493,244 489,942 0.7% Pharmaceutical Supply 1,191,224 1,168,005 2% 403,294 433,860 -7.1% Patient-Specific Therapies 161,574 174,961 -7.7% 54,057 56,012 -3.5% International Business
Slide 25: Key figures (2/2)
Appendix Key figures (2/2) in € thousand 9M 2024 9M 2023 ∆ in % Q3 2024 Q3 2023 ∆ in % Earnings per share (in €) Undiluted 0.43 0.69 -37.7% 0.16 0.30 -46.7% Diluted 0.43 0.69 -37.7% 0.16 0.30 -46.7% Investments (CAPEX) 3,557 861 >100% 1,773 314 >100% Cash flow from operating activities 27,577 10,806
Slide 26: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag
Slide 27: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 28: Q3/9M 2024 Results
Q3/9M 2024 Results Matthias Gaertner, CEO Falk Neukirch, CFO November 12, 2024